RNA Drug Plozasiran Cuts Triglycerides 59% in Dangerous Genetic Lipid Disorder

Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder in which loss-of-function mutations — most often in lipoprotein lipase — prevent the normal clearance of triglyceride-rich chylomicrons from the bloodstream. The result is extreme hypertriglyceridemia that carries a high risk of recurrent acute pancreatitis, a potentially fatal complication. Conventional triglyceride-lowering therapies, including fibrates, omega-3 fatty acids, and niacin, provide inadequate relief in FCS because the underlying enzymatic defect renders these pathways largely irrelevant.

Apolipoprotein C-III (apoC-III) has emerged as a pivotal regulator of triglyceride metabolism. By inhibiting lipoprotein lipase and impairing hepatic clearance of remnant particles, elevated apoC-III amplifies hypertriglyceridemia. RNA-based gene-silencing strategies that suppress APOC3 expression therefore represent a mechanistically logical therapeutic approach.

This expert review, published in Expert Review of Endocrinology and Metabolism, compares FCS with more common multifactorial chylomicronemia and systematically evaluates the landscape of novel therapies. Traditional management and its limitations are outlined, followed by a discussion of non-traditional options — orlistat, lomitapide, ANGPTL3 inhibitors, and FGF21 analogs. The primary focus is on three RNA-based therapeutics: the siRNA plozasiran and the antisense oligonucleotides volanesorsen and olezarsen.

In the phase 3 trial of plozasiran, median placebo-adjusted reductions in apoC-III reached approximately 90%, and triglyceride levels fell by up to 59% at 10 months. These magnitudes of effect far exceed what conventional pharmacotherapy achieves. The authors highlight differences in efficacy and tolerability across the RNA-based agents, noting that plozasiran's siRNA mechanism allows quarterly dosing and may offer an improved safety profile compared with earlier antisense approaches.

The clinical implications are substantial: for patients with FCS who have historically cycled through ineffective treatments and repeated hospitalizations for pancreatitis, these RNA-based therapies represent genuinely transformational options. Physicians managing severe hypertriglyceridemia should be aware of this therapeutic class. Limitations include that this summary is based on the abstract only, and the full comparative safety and long-term durability data require review of the complete article.